AAPG · NASDAQ
Ascentage Pharma Group International
$14.87 +1.39 (+10.31%)
Company overview
Ascentage Pharma Group International is a clinical-stage biotechnology company based in Suzhou, China, that develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. The company's leading product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. Its pipeline also includes APG-2575, an oral Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral MDM2-p53 protein-protein interaction inhibitor for solid tumors and hematological malignancies; and APG-1252, a dual Bcl-2 and Bcl-xL inhibitor for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $346M
- Employees
- 567
- Headquarters
- Suzhou
- Website
- ascentage.cn
- CEO
- Dajun Yang
- Listed
- January 24, 2025
- P/E
- -0.79
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.5B
- Gross profit
- $1.4B
- Operating income
- -$1.6B
- EBITDA
- -$1.4B
- Net income
- -$1.6B
- EPS
- -$18.88
- Total assets
- $4B
- Total debt
- $2B
- Gross margin
- 92.29%
- Net margin
- -105.66%
- Earnings yield
- -126.97%
AAPG
1D
NASDAQ
O13.78H13.78L13.48C13.48-0.08 (-0.59%)Vol1.82K
News